EXEL insider trading
NasdaqGS HealthcareEXELIXIS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About EXELIXIS, INC.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Company website: www.exelixis.com
EXEL insider activity at a glance
FilingIQ has scored 1,374 insider transactions for EXEL since May 28, 2015. The most recent filing in our index is dated May 7, 2026.
Across the full history, 7 open-market purchases
and 404 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on EXEL insider trades is 65.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest EXEL Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding EXEL
Politicians who have traded EXEL
Frequently asked
- How many insider trades does FilingIQ track for EXEL?
- FilingIQ tracks 1,374 Form 4 insider transactions for EXEL (EXELIXIS, INC.), covering filings from May 28, 2015 onwards. 42 of those were filed in the last 90 days.
- Are EXEL insiders net buyers or net sellers?
- Across the full Form 4 history for EXEL, 7 transactions (1%) were open-market purchases and 404 (29%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does EXEL insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is EXEL in?
- EXELIXIS, INC. (EXEL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $11.71B.
Methodology & sources
Every EXEL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.